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SUMMARY 
Preclinical studies have shown that β-adrenergic receptor (β-AR) 
signaling can inhibit multiple cellular processes involved in melanoma 
progression and metastasis. These observations suggest the possibility 
that β-AR blockers, drugs originally intended for the treatment of 
cardiovascular diseases, may provide new therapeutic opportunities for 
the control of tumor progression. A large number of observational 
studies have demonstrated the protective effect of β-blockers in breast 
cancer but, more recently, similar findings were also reported in other 
cancers, such as prostate cancer and melanoma. Regarding  
melanoma, three recently published studies demonstrate a great 
reduction in the risk of disease progression for each year of treatment 
with β-blockers. The results from these studies have suggested a 
potential role for targeting the β-AR pathway in melanoma patients. The 
purpose of this thesis is to present the clinical data obtained from two 
analyses: a retrospective study and an open-label trial, both aimed at 
evaluating the role of β-blockers in melanoma patients. In the 
retrospective study, two subgroups were identified from the medical 
records of 121 consecutive patients with a thick melanoma. Of these, 
30 had been prescribed β-blockers for 1 year or more (treated 
subgroup), whereas the other 91 were untreated. 45 percent of patients 
in the untreated group showed disease progression, which occurred in 
only 30% of the patients in the treated group; 8 (27%) deaths were 
observed in the treated group, whereas in the untreated group 38 (42%) 
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patients died. In the open-label clinical trial, we selected adult patients 
who were at higher risk of disease progression. We divided patients in 
two groups: treated with β-blockers, and untreated. Treated patients 
were eligible for the study with no exclusion criteria, and fulfilled 
inclusion criteria. Patients included in the treated group voluntarily 
accepted to take propranolol 80 mg/R as an off-label treatment for their 
melanoma.  Patients included in the untreated group were those who 
had contraindications to propranolol or who refused to take an off-label 
treatment for their melanoma but accepted to be part of the study as 
controls. The participants were asked to return to the recruitment clinic 
every 6 months. We enrolled 54 subjects, 19 in the treated group and 
34 in the untreated group.  After a median follow-up of 3 years, 41.2% 
(n=14) of the patients in the untreated group showed disease 
progression, which occurred in only 15.8% (n=3) of the patients in the 
treated group. It is notable that in the untreated group six patients 
(17.7%) died for melanoma but only two patients (10.5%) died in the 
treated group and one of them died for a reason unrelated to 
melanoma, from a traumatic event. When time to progression was 
analyzed, log-rank test showed that an improved disease-free survival 
(DFS) for the treated group (P=0.04). Despite the numerous limitations, 
these studies reinforce the hypothesis that β-blockers could provide 
clinically valuable benefits against melanoma progression, possibly by 
inhibiting the pro-metastatic effects of β-AR signaling on tumor immune 
responses and the tumor microenvironment. 
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1 INTRODUCTION 
The burden of personal and emotional factors in cancer etiology and 
outcome has been highlighted several times in medical and non-
medical literature1-4. In the scientific field, epidemiological and clinical 
studies have linked psychosocial factors, such as chronic stress and 
depression, with cancer progression and, to a lesser extent, cancer 
onset5-6. These effects are mediated through the activation of the 
autonomic nervous system and the hypothalamic–pituitary–adrenal 
axis, with the release of catecholamines and other stress hormones. In 
this thesis, we focus on the role of blockade of the sympathetic nervous 
system mediators, epinephrine (EPI) and norepinephrine (NE). In 
preclinical studies, both of these neurotransmitters have been shown to 
impact numerous pathways essential for tumor progression and 
metastasis through both direct and indirect effects on the tumor 
microenvironment. Preclinical studies have demonstrated that the 
protumor and prometastatic effects of EPI and NE are mediated 
primarily through the β-adrenergic receptor (β-AR) signaling pathway7. 
This finding has led a number of authors to hypothesize that the 
commonly prescribed class of β-AR antagonist drugs (β-blockers) may 
positively impact cancer progression8-12.   
Whether prolonged treatment for concomitant diseases, such as 
hypertension, may negatively or positively affect the risk or progression 
of cancer has been addressed repeatedly. Despite a recent alarming 
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report13, a series of studies on the carcinogenic or anticarcinogenic 
potential of antihypertensive agents has consistently shown them to be 
safe. β-Adrenoceptor antagonists (henceforth referred to as β-blockers) 
are among the most widely used antihypertensive agents14. In addition 
to hypertension, β-blockers are prescribed for ischemic heart disease, 
chronic heart failure, anxiety, chronic tremor, migraine, and glaucoma. 
There is initial epidemiological evidence that β-blockers may provide 
protection against the risk of development of cancer. Indeed, β-blocker 
use has been associated with a reduced risk of prostate cancer15 and, 
more recently, with reduced distant metastases, cancer recurrence, and 
cancer-specific mortality in breast cancer16. 
Results of experiments conducted in vitro confirmed the assumption 
that stress is a cofactor in melanoma progression. A study by Glasner 
et al. demonstrated that stressor events could influence numerous 
activities of cellular immunological and endocrinological functions17. As 
a consequence, other studies tried to identify the role of stress factors in 
tumor progression (e.g., angiogenesis and tumor metastasis)18. These 
studies underline the role of matrix metalloproteinases (MMPs) and 
vascular endothelial growth factors (VEGF). MMPs are enzymes that 
digest extracellular matrix molecules, and are involved in the turnover of 
the extracellular matrix in tumor growth and progression. VEGF is a 
well-known cytokine that plays a key role in endothelial cell proliferation; 
therefore, it is a central cytokine for tumor angiogenesis. It has been 
demonstrated in models of ovarian cancer that catecholamines NE and 
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EPI may influence the progression of the tumor by modulating the 
expression of MMPs and VEGF19-21. In vivo studies in mice (B16 
melanoma mouse tumor model) have demonstrated that mice present 
an increase in tumor growth that is totally abrogated by the 
administration of β-blockers. Angiogenesis is a key process in the 
progression of melanoma and metastasis, and therefore the expression 
of VEGF and other interleukins, such as IL-6 and -8, is essential for 
melanoma development22. In 2009, Yang et al. studied in vitro the 
influence of NE in the expression of VEGF. They showed that 
melanoma tumor cells exposed to NE were induced to up-regulate the 
expression of high levels of VEGF, and IL-6 and -8. These results 
support the role of β-ARs in the NE-dependent effect demonstrated 
when propranolol entirely inhibited the NE up-regulation of gene 
expression of VEGF in melanoma tumor cells. These data support the 
hypothesis that NE can stimulate the aggressive potential of melanoma 
tumor cells, in part by inducing the production of VEGF, and IL-6 and -8. 
This line of research further suggests that interventions targeting 
components of the activated sympathetic–adrenal medullary axis or the 
utilization of β-AR- blocking agents may represent new strategies for 
slowing down the progression of malignant melanoma. 
The purpose of this thesis is to estimate the role of β-blocker therapy in 
melanoma patients through two studies: a retrospective study and an 
open-label trial.  First, we retrospectively evaluated the disease-free 
survival and overall survival of melanoma patients treated with β-
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blockers for hypertension (or other diseases) compared to untreated 
patients. In addition, we conducted an open, off-label trial on melanoma 
patients with thick melanoma. We divided the subjects into two groups: 
treated and untreated. We prescribed off-label Propranololo 80mg R 
daily to the treated group, and evaluated overall survival and disease-
free survival. 
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1.1 Melanoma 
Among all skin cancers, melanoma is the most aggressive, with 
increasing incidence worldwide and a high potential of metastatic 
spread. Survival rates in the metastatic stage are poor and therapy is 
limited. While many aspects of the etiology of melanoma are not yet 
clearly understood, several risk factors have been described and will be 
discussed later in this thesis23-25. In recent years, research on 
melanoma has been progressing rapidly, and genetic and immunologic 
factors associated with melanoma development and progression have 
been identified, offering avenues for new therapeutic strategies, 
including immunomodulation and targeted agents. 
1.1.1 Epidemiology: incidence and mortality 
The incidence of cutaneous melanoma has been increasing worldwide 
in white populations for several decades, especially in young adults and 
women, making melanoma one of the most rapidly increasing cancers 
in white populations13, 26-27. The highest incidence rates have been 
reported in Australia and New Zealand28, and approximately 132,000 
cases of melanoma are reported globally each year29. For 2013, it is 
estimated that there will be 76,690 new melanoma cases with 9480 
deaths16. In addition, approximately 61,300 melanomas in situ will be 
newly diagnosed in 201316. As melanoma is generally detected at an 
early invasive stage (T1), the 5-year survival rate is above 90% for 
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women and 87% for men in Western Europe and North America30. 
However, survival from melanoma is poorer in older patients and when 
it is diagnosed at a later stage31. Once melanoma has spread and 
metastases have developed, the overall survival rate is dismal: while 
the 5-year survival rate in patients without metastases is about 98%, it 
is only about 15% in patients with distant metastatic disease16.  
1.1.2 Pathogenesis 
Melanoma is a neoplasm that originates from melanocytes, a 
specialized cell type located in the epidermis that is responsible for the 
production of the melanin pigments. Two types of melanin determine 
phenotypic features: while the reddish-yellow eumelanin is predominant 
in light-complexioned subjects (grey, blue, or green eyes; blond or red 
hair; freckles), the dark pheomelanin is found in dark-complexioned 
subjects (brown eyes; dark hair)32-33. Melanoma can develop on pre-
existing moles such as a congenital, acquired, or atypical nevus, but 
more than half of all melanomas develop de novo34. Several risk factors 
associated with the development of melanoma have been identified and 
will be discussed in the next section.  
Environmental risk factors: Ultraviolet (UV) radiation, one major risk 
factor for melanoma development, was described in 1991 by the 
consensus panel Sunlight, Ultraviolet Radiation, and the Skin35. Later 
studies have confirmed that UV radiation is the major environmental risk 
factor and that people who are intermittently exposed have a higher risk 
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of developing melanoma36. A history of sunburn was also identified as 
an important risk factor, and the risk is slightly higher for sunburns 
experienced in childhood compared with those in adulthood. The 
association between sunburns and melanoma was greater at higher 
altitudes, although studies carried out at lower altitudes were also able 
to demonstrate an association between sunburns and melanoma. One 
explanation for why UV radiation is so damaging is that it leads to cell 
and DNA damage and thus increases the risk of mutation37. People with 
signs of actinic damage of the skin, such as solar lentigo, elastosis, 
actinic keratosis, and nonmelanocytic cutaneous tumors (eg, squamous 
cell carcinoma and/or basal cell carcinoma), are at higher risk of 
developing melanoma. 
Acquired and genetic risk factors: The number of congenital or 
acquired common and atypical nevi is a very important independent risk 
factor for the occurrence of melanoma38. The term “atypical nevi” is 
frequently used for nevi that are clinically suspected of underlying 
dysplasia. Having numerous moles is possibly related to a genetic 
predisposition for melanoma development. Increased UV radiation 
exposure may not only lead to the development of multiple moles but 
also to an increased risk of melanoma transformation. The Fitzpatrick 
standard classification distinguishes different skin types according to 
the color of the skin and eyes and the patient’s burning or tanning 
response to sunlight exposure. Photosensitivity is increased in people 
with a light complexion and freckles compared to people with a dark 
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skin type, and an association of photosensitivity with melanoma is 
assumed. It should also be noted that constitutional UV sensitivity is not 
only a risk factor for the development of melanoma, but also for 
nonmelanoma skin cancers, such as squamous cell carcinoma and/or 
basal cell carcinoma in whites. Personal history of a previous 
melanoma and a positive family history of melanoma, usually defined as 
the diagnosis of melanoma in one or more affected first-degree relative, 
is associated with a higher risk for the development of melanomas39.  
Immunologic factors: Two components of the immune system, the 
humoral and the cell-mediated immune response, are considered of 
utmost importance for antitumor immunity40. One of the most important 
mechanisms is the elimination of tumor cells by cytotoxic CD8+ T 
lymphocytes. However, cancer cells are able to modify immunologic 
pathways and interactions to their own advantage and survival40. 
Mechanisms assumed to lead to tumor resistance include 
downregulated or disabled antigen presentation, immunologic barriers 
within the tumor microenvironment, negative regulatory pathways 
targeting T-cells, or T-cell dysfunction41. For example, one critical 
inhibitory signal is mediated by the interaction between cytotoxic T 
lymphocyte antigen-4 (CTLA-4) on T-cells and its ligands (B7–1 and 
B7–2) on antigen-presenting cells42. CTLA–4 is not strongly expressed 
on naive T-cells but becomes rapidly induced after T-cell activation: the 
mechanism that prevents undesired autoimmunity and establishes 
tolerance to self-antigens by downregulating T-cell activation via a 
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homeostatic feedback loop. However, this downregulation mechanism 
can be modified in melanoma to disrupt the normal T-cell function, 
leading to a decreased antitumor response. The expanding knowledge 
of immunologic processes in melanoma has resulted in the 
development and application of different immunomodulation therapy 
approaches (eg, interferon, vaccines) in order to support the body’s 
tumor defense mechanisms. In recent years, selective antibodies, such 
as the CTLA-4 antibody ipilimumab, have been explored as effective 
therapy strategies. 
1.1.3 Prevention and screening 
Prevention (primary prevention): Sun exposure is a major causative 
factor in the development of melanoma. Therefore, efforts to educate 
the general public about the risks of sun exposure and to support sun 
avoidance (particularly important in childhood) have been made. In 
Australia, behavioral changes have been observed (e.g., wearing sun-
protective clothing on the school playground, less reported tanning and 
sunburns), but such campaigns were not equally successful in other 
countries, and sun exposure and tanning are still popular 43. Although 
there is currently a lack of evidence that primary prevention leads to a 
decrease in overall melanoma-specific survival, it offers the potential to 
positively influence mortality in the long term. Whether sunscreen 
protects against cutaneous melanoma has not been fully proven. 
However, sunscreen has been shown to reduce the risk of squamous 
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cell carcinoma, so its use is advisable as well. People need to be 
informed that the application of sunscreen should not be used to 
increase the time spent in the sun, and that sensible sun-protective 
behavior is mandatory (e.g., avoidance of sun exposure, especially 
between 11 AM and 3 PM)44. In addition to sunscreen, the use of sun-
protective clothing (e.g., hats, sunglasses) is recommended, as that can 
minimize the amount of solar UV radiation exposure45. 
Screening (secondary prevention): Screening programs can initially 
lead to a greater incidence of melanoma due to increased detection, but 
may eventually reduce tumor burden and thus decrease mortality, as 
was shown in Germany during and after SCREEN (Skin Cancer 
Research to Provide Evidence for Effectiveness of Screening in 
Northern Germany), the world’s largest screening project46. The reason 
for both is that melanoma is detected at an earlier stage, and excision 
of thin or in situ melanoma offers the possibility of mortality reduction in 
the short term47. Even if screening programs are currently not 
implemented worldwide, there is hope that melanoma deaths can be 
reduced through prevention and screening. 
1.1.4 Clinical features and classification  
Clark et al. 48 were the first to divide melanoma into subtypes 
depending on clinical and histologic features, criteria that were later 
used by other researchers49. The majority of all melanomas fall into the 
following four subtypes (the World Health Organization [WHO] 
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classification of melanoma)50: superficial spreading, nodular, lentigo 
maligna, and acral lentiginous. Precursor lesions with no penetration of 
the basal membrane but with a high risk of transforming into melanoma 
are called “melanoma in situ” or “lentigo maligna.” The superficial cells 
of the primary lesion, either intraepidermal or just below the basal 
membrane, determine the classification of melanoma. Lesions without 
pigment are classified as “amelanotic”. Nodular and acral lentiginous 
melanomas have the poorest 5-year survival rates among all 
histological subtypes (69.4% and 81.2%, respectively), mainly because 
of their higher tumor thickness at the time of diagnosis51.   One rare 
melanoma subtype is the desmoplastic melanoma that is often 
amelanotic and can be difficult to diagnose. Histopathologically, 
perineural invasion is an atypical feature of this desmoplastic 
melanoma.  
Genetic alterations in melanoma subtypes:  Cutaneous melanoma is 
a heterogeneous disease with different clinicopathologic subtypes. 
However, in clinical practice, a substantial number of melanomas do not 
fit into the classic subtypes. More recently, mutation analyses showed 
that melanomas can also be classified according to distinct genetic 
alterations in different pathways, which also helps to better understand 
why melanomas develop, and explains some of the biologic features52. 
These findings served as the foundation for the development of the first 
targeted therapies in melanoma. Another approach for a genetic 
classification of melanomas, proposed by Bastian et al., relates to their 
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preferential body site of occurrence and exposure to ultraviolet (UV) 
radiation53. Mutations in BRAF and chromosomal losses (chromosome 
10) were shown to occur significantly more often in melanoma of 
intermittently sun-exposed skin, while mutations in NRAS were mostly 
found in melanoma in sun-protected areas (e.g., acral lentiginous 
melanoma). The role of sun exposure or sun damage to the skin in the 
development of acral lentiginous melanoma is assumed to be of lesser 
importance.  
American Joint Committee on Cancer Staging and Classification: 
Melanoma staging is based on the American Joint Committee on 
Cancer (AJCC) TNM classification system (T=tumor, N=nodes, 
M=metastases), which was developed in 2009 on the basis of long-term 
follow-up data of more than 38,000 patients54. The anatomic stage 
groupings for cutaneous melanoma are based on the TNM staging. 
Compared to previous classification systems (eg, AJCC 2002), mitotic 
rate has been added as a prognostic factor in low-risk melanoma, 
replacing the level of invasion (Clark level). According to the TNM 
classification, the Clark level is only used for the subdivision between 
T1a and T1b if the mitotic rate was not assessed. Sentinel node biopsy 
is required for the correct N-classification. Patients with melanoma of 
unknown primary should be allocated to stage III (in case of skin and/or 
lymph node metastases) or IV disease, depending on the site(s) of 
metastases. 
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1.1.5. Prognostic factors 
The following risk factors are described and incorporated into the 2009 
AJCC classification system: 
• Tumor thickness is the most important prognostic factor. In 
patients with melanomas with tumor thickness ≤1.00 mm, the 
10-year survival rate was shown to be about 92%, compared 
with 80% in patients with melanomas of 1.01–2.00-mm 
thickness, 63% in patients with melanomas of 2.01–4.00-mm 
thickness, and 50% in patients with melanomas of >4.00-mm 
thickness. 
• Ulceration has an important influence on survival. Patients 
with an ulcerated T4 melanoma (pT4b) have a 5-year survival 
rate of 53%, while the survival rate for patients with a 
nonulcerated T4 primary (pT4a) ranges around 71%.  
• The mitotic rate is a marker for the proliferation of the 
primary melanoma. A highly significant correlation between 
increasing mitotic rate and declining survival rates was 
demonstrated. The most significant correlation with survival 
was identified  at a threshold of at least 1/mm2. Survival rates 
of patients with an ulcerated primary or elevated mitotic rate 
are lower than those of patients with a nonulcerated 
melanoma of equivalent T-category.  
• Nodular involvement-related survival rates differ due to 
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heterogeneity. Tumor burden at the time of staging 
(microscopic versus macroscopic) was shown to be a further 
prognostic factor. Five-year survival rates within stage III 
were 78%, 59%, and 40% for patients with stage IIIA, IIIB, 
and IIIC melanoma, respectively.  
• Prognosis is worse in patients with distant metastases. 
Lactate dehydrogenase (LDH) is a highly significant 
predictor of survival or outcome in stage IV patients, 
independent of other factors. When elevated LDH levels are 
found, patients are classified as M1c regardless of the 
location of distant metastases. One-year survival rates are 
approximately 62% (M1a), 53% (M1b), and 33% (M1c), 
respectively. Survival rates after 10 years range between 5% 
and 20% [12].  Other clinical factors of prognostic importance 
for survival include gender (males with poorer prognoses than 
females), increasing patient age, and location of the primary 
tumor (trunk and head sites have poorer prognosis than 
extremities)55; however, these factors are not included in the 
2009 AJCC classification system.  
1.1.6 Diagnosis and staging 
After carefully taking the patient’s medical history, their individual risk 
factors for melanoma should be assessed and evaluated. Patients 
should be asked if they have noticed the development of new lesions or 
changes in pre-existing ones. For the detection of clinically suspicious 
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lesions, a detailed visual examination comprising the entire skin 
(including the hairy scalp) as well as the visible parts of the oral and 
genital mucosa is required. The ABCD rule can serve as a clinical 
guideline to distinguish between benign and early malignant lesions 
during examination with the naked eye: 
• A = Asymmetry in shape  
• B = Border irregularity  
• C = Color variation  
• D = Diameter greater than 6 mm   
• Some authors have proposed E as an additional criterion, thus 
described: E = evolving, elevation, or enlargement. Furthermore, 
the term “evolving” seems particularly important since it includes 
changes over time with respect to size, shape, shades of color, 
surface features, or symptoms 56.  
Any history regarding change in symptoms associated with pigmented 
lesions is important to render appropriate management decisions and to 
decrease thresholds for excision. It is important to note that not all 
melanomas present with all criteria, and unrelated dermatological 
disorders, for example, seborrheic keratosis and granuloma 
pyogenicum, can share some of these properties. Nevertheless, it is the 
combination of the ABCD(E) features (eg, ABC or A and D) that most 
often arouses suspicion of early melanoma in a melanocytic lesion. 
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Inspection of the pigmented lesions in the surrounding area of a 
suspicious lesion is important, particularly in the setting of multiple (dys- 
plastic/atypical) nevi. Every individual has unique clinical dermoscopic 
patterns of nevi (i.e., nevi in the same individual usually resemble one 
another). A lesion that looks different (so-called “ugly duckling sign”) 
can be a helpful indicator for melanoma57. Once a clinically suspicious 
lesion has been detected and confirmed, the physical examination 
should also include palpation of the locoregional lymph nodes as well 
as the in-transit region (the area between the primary tumor and the first 
draining lymph node basin). 
Dermoscopy: Dermoscopy is a useful tool for improving diagnostic 
accuracy, as it enhances melanoma detection and decreases the 
number of unnecessary excisions58. It is a noninvasive diagnostic 
technique and consists of a hand-held magnifier and a light source. To 
reduce surface light-scatter interference, an interface immersion fluid is 
applied between the transparent plate and the skin. Other dermoscopes 
use polarized light and can be utilized without a liquid medium. Training 
and experience are mandatory for dermoscopy as the practice by 
untrained or less experienced examiners has been demonstrated to be 
no better than clinical inspection without dermoscopy. Multiple 
dermoscopic features have been described and several diagnostic 
approaches proposed, including the Menzies method, a 7-point 
checklist for dermoscopic scoring of atypical melanocytic lesions59.  
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Biopsy 
The clinical diagnosis should be confirmed by a timely skin biopsy, with 
the excision of the entire lesion as the recommended standard of 
care60. Accordingly, lesions suspicious of melanoma should be excised 
completely with a narrow lateral margin of approximately 2 mm or 3 mm 
of normal skin and vertically reaching into the subcutaneous fat tissue. 
Larger margins could cause disruption of local lymphatic vessels and 
consequently complicate the detection of the correct lymph nodes, and 
therefore should be avoided. Tangential excision by shave or partial 
excision is not generally recommended, even if it is most likely not 
associated with an unfavorable prognosis, as deeper-lying melanoma 
deposits could remain in the skin impeding an accurate diagnosis of the 
tumor thickness and its horizontal size. However, partial excision or 
punch-biopsy may be acceptable in large and widespread tumors in the 
face, mucosal, or acral locations. 
1.1.7 Treatment of primary tumor  
After the initial excision of the primary tumor with a narrow resection 
margin and pathologic confirmation of cutaneous melanoma, the 
subsequent standard treatment is wide surgical excision to remove 
melanoma cells that may be present in the adjacent tissue. The 
pathological examination of the specimen should confirm the 
completeness of the tumor excision and check for satellite metastases, 
as surgery can be curative, especially in tumors with low thickness and 
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in the absence of metastatic spread, and can reduce the risk of local 
recurrence. Available data on the extent of wide local excision for the 
treatment of melanoma are not unequivocal, and there is ongoing 
discussion on the optimum resection margins. However, several studies 
and meta-analyses have demonstrated that narrow excision margins 
are as safe as wide margins in the management of primary melanoma. 
The recommendations for the extent of the radial surgical excision 
margins are based on the Breslow tumor thickness of the primary 
melanoma. The vertical excision depth should include the 
subcutaneous tissue down to, but not including, the muscular fascia or 
the respective underlying structures, such as cartilage or muscle in 
areas without muscular fascias (e.g., the face).  
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1.2 Literature Review 
1.2.1 Hypertension and Risk of Cancer 
Over the past 30 years, mortality from cardiovascular diseases has 
dramatically decreased due to the introduction of new drugs and 
integrated therapeutic strategies. Among the more recently introduced 
drugs, inhibitors of the renin–angiotensin system and β-blockers have 
gradually acquired a predominant role in the treatment of cardiovascular 
and metabolic disease, finding multiple indications for clinical conditions 
including hypertension, myocardial infarction, heart failure and 
nephropathy, among others. A recent study published in Lancet 
Oncology in 2010 demonstrated an increased risk of cancer associated 
with chronic intake of angiotensin receptor blockers, raising questions 
about the association of antihypertensive drugs and cancer61. The 
carcinogenic potential of antihypertensive drugs has been debated for 
more than three decades, with studies producing conflicting data. 
However, a more recent and comprehensive meta-analysis published in 
Lancet Oncology in 2011, which took 70 studies into consideration, 
demonstrated no association between intake of antihypertensive drugs, 
such as angiotensin receptor blockers, β-blockers or diuretics, and a 
higher risk of mortality or of developing cancer62. In addition, at the 
current time, other evidence suggests that some of these 
antihypertensive drugs can play a protective role against tumors. 
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1.2.2 β-blockers and Risk of Cancer  
Breast Cancer: Six recently published pharmacoepidemiological 
studies have examined the association between β-blocker exposure 
and breast cancer progression63. In the first of these studies, Powe et 
al. reviewed medical records to identify female patients with stage I and 
II breast cancer 64. In this study, Powe et al. demonstrated a 57% 
reduced risk of metastasis development and a 71% reduction in the risk 
of breast cancer-specific mortality after 10 years when adjusting for 
tumor size, stage, and grade in women taking any β-blocker compared 
with those who were not. Ganz et al. examined associations between 
any β-blocker exposure and/or angiotensin-converting enzyme inhibitor 
exposure and breast cancer outcomes65. In this paper, he compared 
the time to breast cancer recurrence, breast cancer-specific mortality, 
and overall mortality between exposed and unexposed groups with β-
blocker use. In comparison with unexposed women, women taking β-
blockers had a 14% reduction in the risk of breast cancer recurrence 
and a 24% reduction in the risk of breast cancer-specific mortality. In a 
study by Melhem-Bertrandt et al., the authors found that women taking 
β-blockers had a 48% reduction in the risk of breast cancer recurrence 
and a statistically significant 36% risk reduction of death66. In a study by 
Barron et al., the authors linked national cancer registry and 
prescription refill data from Ireland to identify 5801 women with a 
diagnosis of stage I–IV invasive breast cancer67. Women taking 
propranolol at the time of diagnosis had an 81% lower risk of breast 
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cancer-specific mortality after adjusting for age, stage, grade and 
comorbidity score. In a study by Shah et al., the authors used a primary 
care database in the UK to identify women with a diagnosis of breast 
cancer who also filled at least two prescriptions for an antihypertensive 
agent in the year prior to diagnosis68. Patients taking a β-blocker were 
compared with patients taking other antihypertensive therapy. In the 
breast cancer analysis, there was no difference in overall survival 
between patients receiving any β-blocker and patients receiving other 
antihypertensive medications. In a study by Sendur et al., the authors 
reported the results from an age-matched retrospective analysis of 
breast cancer outcomes in users and nonusers of the β1-selective 
antagonist metoprolol69. They found no significant differences in 3-year 
disease-free or 5-year overall survival rates between metoprolol users 
and nonusers. However, in consideration of the variation of the 
percentage of mortality rates in patients affected with breast cancer, 
these studies have a low level of evidence. 
Colorectal Cancer: With respect to the risk of developing colorectal 
cancer (CRC), one study reported a risk reduction of 21% when 
comparing β-blocker users with users of diuretics70; however, 
adjustment for confounding factors was not performed. Another large 
study that screened pharmaceuticals for possible carcinogenic effects 
found no association of colon or rectal cancer risk with the use of β-
blockers; again, detailed adjustment for confounding factors was not 
possible, as the study was based on prescription databases. A recently 
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published paper71 investigated the use of β-blockers with respect to risk 
of colon cancer in a large population-based case-control study with 
detailed assessment of putative and established CRC risk and 
preventive factors including medication. 
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1.2.3 β-blockers and Melanoma Progression 
Three recently published pharmacoepidemiological studies have 
examined the association between β-blocker exposure and melanoma 
progression. The first paper regarding the use of β-blockers in 
melanoma patients was published by De Giorgi et al. in 2011 in the 
Archives of Internal Medicine72. In this study, the authors reviewed the 
prospectively accrued clinical records of patients who were 
histologically diagnosed as having malignant melanoma from 1993 to 
2009 at the Department of Dermatology at the University of Florence, 
Italy. In this report, the authors selected patients who were at higher risk 
of disease progression based on Breslow thickness greater than 1 mm. 
Disease progression was assessed by evaluating the presence of 
sentinel lymph node metastases and lymphatic, in-transit or visceral 
metastases. Deaths by any cause and deaths due to melanoma were 
recorded, and the time to death was defined as the time interval that 
elapsed after the initial diagnosis. The database contained information 
on any administered medications, including dosage and treatment 
duration. Information on medications was obtained by interviewing the 
patients during their first visit and at each follow-up visit (every 6 
months). In this study, patients were considered treated if they reported 
β-blocker use for at least 1 year, whereas untreated patients were those 
who reported no β-blocker use or β-blocker use for less than 1 year. A 
total of 121 patients with thick melanoma were included in the study. Of 
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the 121 patients with thick melanoma, 30 patients were included in the 
treated group and 91 patients comprised the untreated group. The 
median duration of β-blocker use in the treated group was 5 years. 
Among the untreated patients, 90 patients never used β-blockers and 
one patient used β-blockers for less than 1 year. The two groups were 
comparable in terms of demographic characteristics and primary 
prognostic factors at baseline, except for age. After a median follow-up 
of 2.5 years (interquartile range: 1.2–5.0), 34% of the patients in the 
untreated group had evidence of disease progression, while only 3% of 
the patients in the treated group showed progression. Notably, 19% of 
the patients in the untreated group were positive for sentinel lymph 
nodes, without further evidence of metastases, compared with only 3% 
of the patients in the treated group (p = 0.04). When the time to 
progression was analyzed, the log-rank test demonstrated that disease-
free survival was significantly greater in the treated group (p = 002). 
After adjusting for age and Breslow thickness, the Cox model indicated 
that treatment with β-blockers was inversely associated with recurrence 
(hazard ratio: 0.03; 95% CI: 0.01–0.28; p = 01). Furthermore, consistent 
results were obtained when the authors considered duration of 
treatment: a 36% reduction (95% CI: 11–54%) in risk of relapse for 
each year of β-blocker use was determined by the Cox model (p = 002). 
The most striking piece of data that emerged from the study was that no 
deaths related to melanoma occurred during the study period in the 
treated group, and all 24 patients who died of melanoma during the 
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follow-up period were in the untreated group (p < 0.001). 
Despite the small sample size and consequently weak results of the 
study by De Giorgi et al., a larger retrospective study that has been 
published by Lemeshow et al. confirmed the results73. In their report, 
Lemeshow et al. conducted a population-based cohort study in northern 
Denmark within a population of 1.7 million (about 30% of the total 
Danish population). As the Danish National Health Service provides 
universal tax-supported healthcare guaranteeing unrestricted patient 
access to general practitioners and hospitals, and partial 
reimbursement for prescribed medications, including β-blockers, they 
have a unique central personal registry number assigned to each 
Danish citizen at birth and to residents upon immigration. This allows for 
simplified linkage among national registries. 
They identified all patients with an incident diagnosis of malignant 
melanoma from the Danish Cancer Registry (DCR), which has recorded 
all cancer cases in Denmark since 1943. Registration in the DCR is 
based on notification forms completed by hospital departments and 
practicing physicians when a cancer is diagnosed or found at autopsy, 
or when an initial diagnosis is changed. In the DCR, the extent of 
cancer is classified as localized, regional, metastatic to distant sites, or 
unknown. The entire coding process is supervised by physicians. 
Comprehensive validation has shown that the DCR is 95–98% valid and 
complete. With regard to prescription data, the authors used the 
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prescription database of the region to identify prospectively all 
prescriptions redeemed by the study population of patients with 
melanoma before and after their diagnosis date. The authors obtained 
at least 1 year of prescription history for all members of the study 
population and identified prescriptions for all β-blockers (including 
metoprolol, propranolol and atenolol), statins, angiotensin-converting 
enzyme inhibitors, aspirin, antidepressants, antipsychotics and 
anxiolytics. 
In addition, the authors had access to melanoma mortality and all-cause 
mortality data from the Civil Registration System, which contains 
complete information for the entire Danish population on migration and 
changes in vital status, including exact date of death, updated on a daily 
basis. They also obtained information from the Causes of Death 
Registry, which has recorded data from all Danish death certificates 
issued since 1943. Computerized and validated information from this 
registry is currently available through 2006. Whenever a Danish 
resident dies, the attending physician must report the cause of death; 
the chain of events leading to death can be specified using up to four 
diagnoses. Causes of death recorded during the study period were 
coded according to ICD-10. An intent-to-treat method was used to 
assess β-blocker use. Subjects were assigned to the β-blocker group if 
they were prescribed β-blockers in the 90-day period prior to melanoma 
diagnosis; a second group of patients was identified who were pre- 
scribed β-blockers more than 90 days prior to melanoma diagnosis; 
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otherwise, subjects were assigned to the non-β-blocker group. 
Regarding the 90-day period prior to diagnosis, most Danish 
prescriptions cover 90 days, which ensures high specificity and 
sensitivity to capture β-blocker treatment accurately. 
The study population consisted of 4179 patients diagnosed with 
melanoma. Median follow-up time was 4.9 years with a maximum of 
20.7 years. A total of 660 (15.8%) out of the 4179 subjects with 
melanoma were prescribed β-blockers before their diagnosis. A total of 
372 (8.9%) subjects were assigned to the intent-to-treat β-blocker 
exposure 90 days prior to diagnosis group and used β-blockers for 8.0 
years (mean). A total of 288 (6.9%) subjects had β-blocker exposure 
more than 90 days prior to diagnosis and used β blockers for 2.7 years 
(mean). Both β-blocker group patients were older and took more 
cardiovascular and psychotropic drugs than the group with no prior β-
blocker exposure. The 90-day prior exposure group had higher 
mortality, whereas the more than 90-day prior exposure group had 
lower mortality than the no-exposure group. In addition, a larger number 
of patients in the more than 90-day prior exposure group compared with 
the other two groups had missing or unspecified stage information. The 
wide variety of comorbidities considered in the study generally occurred 
with low frequency in all three groups; however, history of osteomyelitis, 
autoimmune disease, and pneumonia was significantly more common 
in both β-blocker groups. The distribution of CCI scores was collapsed 
to 0, 1, and 2 or more within each of the β-blocker subgroups. Only 
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56% of patients in the 90-day β-blocker exposure group and 51% in the 
more than 90-day β-blocker exposure group had no comorbidities 
compared with 81% in the group with no prior β-blocker exposure. This 
suggests that patients who were prescribed β-blockers prior to 
diagnosis had more underlying chronic conditions (and may have been 
in poorer health) than those not prescribed this medication prior to 
diagnosis. As expected, mortality rates increase with more severe 
disease. The results indicate that for each stage of melanoma, mortality 
rates were higher in the β-blocker groups than in the group not 
prescribed this medication, although statistical significance was reached 
only in the group with stage I and II disease.  
The following study published in Mayo Clinic in 2013 by De Giorgi et al. 
74 to verify preliminary studies on patients with melanoma exposed to β-
blockers confirmed and strengthened previous findings that the use of 
β-blockers is associated with a reduced risk of melanoma recurrence 
and death.  In this last study, data were obtained from all consecutive 
patients diagnosed as having melanoma between January 1, 1993, and 
December 31, 2009, at the Department of Dermatology of the University 
of Florence. Participants were excluded if at baseline they reported a 
previous diagnosis of cutaneous malignant melanoma or another 
malignant disease. Of 741 consecutive patients with melanoma, 79 
(11%) were prescribed β-blockers (for hypertension in most cases) for 1 
or more years (treated) and 662 (89%) were not (untreated). The 
multivariate Cox model indicated that the treated group had improved 
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overall survival after a median follow-up of 4 years (P_.005). For each 
year of β-blocker use, the risk of death was reduced by 38%. The 
presence of hypertension, the use of antihypertensive agents for 1 or 
more years, or the use of other commonly used medicines were not 
associated with a better outcome for patients with melanoma. 
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2 AIM 
The purpose of this thesis is to estimate the role of β-blocker therapy in 
melanoma patients through two studies: a retrospective study and an 
open-label trial.  First, we retrospectively evaluated the disease-free 
survival and overall survival of melanoma patients treated with β-
blockers for hypertension (or other diseases) compared to untreated 
patents.  In addition, we conducted an open, off-label trial on melanoma 
patients with thick melanoma. We divided the subjects in two groups: 
treated and untreated. We prescribed off-label Propranololo 80mg R 
daily to the treated group and we evaluated the overall survival and 
disease-free survival. 
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3 METHODS 
3.1 Retrospective Study - Methods 
We retrospective reviewed the accrued clinical records of patients who 
were histologically diagnosed as having malignant melanoma from 
1993 through 2009 at the Department of Dermatology at the University 
of Florence, Florence, Italy. To select patients who were at higher risk 
of disease progression, only those with thick melanoma (Breslow 
thickness≥1 mm) were included in the analysis. Disease progression 
was assessed by evaluating the presence of lymphatic, in-transit, or 
visceral metastases. Deaths by any cause and deaths due to 
melanoma were recorded, and the time to death was defined as the 
time interval that elapsed after the initial diagnosis. The database 
contained information on any administered medications, including 
dosage and treatment duration. Information on medications was 
obtained by interviewing the patients during their first visit and at each 
follow-up visit (performed routinely at 6-month intervals) and was 
verified by interviewing their general practitioners once a year for the 
study period. Based on previous findings regarding the relationship 
between the duration of β-blockers use and the incident risk of prostate 
cancer, patients were considered treated if they reported beta-blocker 
use for at least 1 year, whereas untreated patients were those who 
reported no β-blockers use or β-blockers use for less than 1 year. This 
study was approved by the ethics committee of the Local Health Unit 10 
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(Florence, Italy). A multivariate Cox proportional hazards model was 
used to evaluate the influence of treatment on DFS and OS, adjusting 
for significant confounders. Since 9 patients in the treated group started 
beta-blocker use after melanoma diagnosis, we took into account of 
possible immortal time bias including β-blockers use as time-dependent 
variable. All statistical tests were 2-sided, and P <.05 was considered 
statisticallysignificant.
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3.2  Open-label Study for Treatment of Melanoma Patients with β-
blockers - Methods 
We conducted an open-label clinical trial in patients who were 
histologically diagnosed as having a higher risk malignant melanoma 
from 1 January 2011 through 1 April 2013 at the Department of 
Dermatology at the University of Florence, Florence, Italy. We selected 
patients who were at higher risk of disease progression. Only patients 
with thick melanoma (Breslow thickness >=1 mm) were included in the 
analysis. Patients older than 18 years of age with histologically 
confirmed thick cutaneous melanoma were eligible for be part of the 
study. After the patients had been informed, and had signed informed 
consent, they were checked for eligibility. We divided the patients into 
two groups: treated with β-blockers and untreated. Treated patients 
were patients eligible for the study with no exclusion criteria and full 
inclusion criteria for the treated group. Patients included in the treated 
group voluntarily accepted to take Propranololo 80mg R daily as an off-
label treatment for their melanoma.  Patients included in the untreated 
group were patients that had exclusion criteria to take propranolol, or 
patients that refused to take an off-label treatment for their melanoma, 
but accepted to be part of the study as control group. 
Inclusion criteria for both groups: 
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1. 18-75 years old with newly diagnosed histologically proven 
resected melanoma; 
2. Stage: Ib (T1b, T2a),  IIa (T2b, T3a), IIb (T3b T4a) and IIc (T4b), 
N0, M0; IIIA (N1a, N1b) ; 
3. Signed Informed Consent. 
Exclusion criteria for both groups: 
1. Primary not cutaneous melanoma; 
2. Presence of metastasis; 
3. Clinical/radiological evidence or laboratory/pathology report of 
not completely resected melanoma; 
4. History of cancer;  
5. Current use or past use in the last two years of any β-blockers 
for any other medical condition.  
Exclusion criteria for treated group: 
1. Current use of verapamil, diltiazem or similar calcium channel 
blockers; 
2. Current use of centrally acting antihypertensive drugs, such 
as α-methyldopa, clonidine; 
3. Hypersensitivity to propranolol or to any of the excipients;  
4. Acute heart failure, or during episodes of heart failure 
decompensation requiring i.v. inotropic therapy; 
5. Cardiogenic shock; 
6. Sinoatrial block ; 
7. Second or third degree atrio-ventricular block;  
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8. Marked bradycardia (less than 60 beats/min) ; 
9. Extreme hypotension (systolic blood pressure <100mmHg) ; 
10. Severe asthma or severe chronic obstructive pulmonary 
disease ; 
11. Sick sinus syndrome;  
12. Severe forms of peripheral arterial occlusive disease and 
Raynaud's syndrome;   
13. Metabolic acidosis; 
14.  Asthma;  
15. Diabetes; 
16. Heart failure; 
17. Pregnancy or breast feeding or planning on becoming 
pregnant during the 3 years of treatment; 
18. Any medical condition that in the physician’s opinion would 
potentially interfere with the patient’s ability to adhere to 
protocol and treatment; 
19. Any logistic conditions that do not allow follow-up of the 
disease of the patient; 
20. Hypersensitivity to propranolol; child bearing or breast 
feeding. 
 
At baseline, we measured anthropometric variables such as weight and 
height. Arterial blood pressure, pulse rate, and ECG were recorded. 
Propanolol 80mg/R was administered daily to eligible patients. 
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Treatment was discontinued in cases of confirmed disease progression 
as determined using modified World Health Organization (mWHO) 
criteria. The participants were asked to return to the recruitment clinic 
every 6 months. The physician performed a complete physical 
examination, including measurement of body weight, blood pressure 
and pulse rate, to assess the general health of the study participant. We 
collected updated information about health status and signs of 
recurrence of melanoma. Study participants were able to withdraw from 
the study at any time. Reason for subject discontinuation may include: 
recurrence, adverse event that compromises the patient’s ability to 
participate in the study, such as serious acute emergencies (i.e., heart 
attack, stroke or acute abdomen surgery). Subjects who discontinued 
treatment were encouraged to participate in the follow-up examinations 
to maintain an intention-to-treat analysis. Disease progression was 
assessed by evaluating the presence of lymphatic, in-transit, or visceral 
metastases.  
Median values, range inter-quartiles, frequencies and results from non-
parametric tests (Wilcoxon signed-rank tests or Chi-squared tests) were 
used to present and analyze the differences of features between Beta-
blocker treated and untreated cohorts of patients. 
Time to death and time to recurrence were defined as the time from 
surgery until the event of interest. All patients alive or free of disease at 
last follow-up date were considered right censored. Disease-free 
survival was estimated by the Kaplan-Meier method. The log-rank tests 
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were used to compare survival time between groups. Cox proportional 
hazards models were used to assess if Beta-Blocker use is 
independently associated with melanoma recurrence and survival, after 
adjustment for confounding and prognostic factors. All statistical tests 
were two-sided, and P<0.05 was considered statistically significant. The 
statistical analyses were performed with the Statistical Analysis System 
Version 9.2 (SAS Institute, Cary, NC). 
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4 RESULTS 
4.1 Retrospective Study - Results 
Of the 749 patients with melanoma who underwent regular follow-up at 
our clinic, 121 with thick melanoma were included in the present study. 
Of the 121 patients with thick melanoma, 30 were included in the 
treated group, and 91 comprised the untreated group. Among the 
untreated patients, 90 never used beat-blockers, and 1 used beat-
blockers for less than 1 year. The 2 groups were comparable in terms of 
demographic characteristics and primary prognostic factors at baseline, 
except for age (Table 1). After a median follow-up of 8 years, 47% of 
the patients in the untreated group showed disease progression, which 
occurred in only 30% of the patients in the treated group. It is notable 
that in the untreated group 35% of patients deaths for melanoma and 
only 17% of patients deaths for melanoma in the treated group (Table 
2). When time to progression was analyzed, the Cox model indicated 
that treatment with beta-blockers was inversely associated with disease 
free survival (HR=0.29; 95%CI, 0.12-0.72; P=.01) and with overall 
survival (HR=0.33; 95%CI: 0.13-0.83; P =.02), adjusting for age, 
gender, Breslow thickness, ulceration, mitoses and hypertension (Table 
3 and Figure 1). 
	   45	  
Table 1: Main clinical and histopathological characteristics of the 
study population divided by β-blocker treatment status.  
 
	   	  
	  
	   Treated	  (a)	  
N=30	  
Untreated	  (b)	  
N=91	  
	  
Gender	  (males)	  
	  
17	  (56.7%)	   49	  (53.8%)	  
	  
Median	  Breslow	  thickness	  (IQR)	  
	  
1.6	  (1.1-­‐3.2)	   1.7	  (1.2-­‐2.7)	  
	  
Site	  of	  primary	  melanoma	  (%)	  
Head	  or	  neck	  
Trunk	  
Upper	  limbs	  
Lower	  limbs	  
Acral	  
Mucosal	  
	  
3	  (10.0)	  
7	  (23.3)	  
7	  (23.3)	  
10	  (33.3)	  
3	  (10.0)	  
0	  (-­‐-­‐)	  
	  
10	  (10.9)	  
40	  (43.9)	  
14	  (15.5)	  
21	  (23.1)	  
5	  (5.5)	  
1	  (1.1)	  
	  
Lesion	  with	  ulceration	  (%)	  
8	  (26.6)	   21	  (23.1)	  
	  
Lesion	  with	  mitosis	  ≥1	  (%)	  
	  
13	  (43.3)	   27	  (29.7)	  
	  
Disease	  Stage	  	  
1B	  
2A	  
2B	  
2C	  
3	  
(at	  the	  time	  of	  the	  diagnosis)	  
	  
18	  (60)	  
2	  (6.7)	  
8	  (26.6)	  
2	  (6.7)	  
0	  
	  
	  
41(45)	  
25	  (27.5)	  
18	  (19.8)	  
3	  (3.3)	  
	  4	  (4.4)	  
	  
 
(IQR= interquartile range) 
 
a) “Treated” indicates patients on β-blockers for ≥1 year. 
b) “Untreated” indicates patients not on β-blockers or on β-blockers for <1 
year.  
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Table 2:  Events during follow-up divided by β-blocker treatment 
 
 Treated  
N=30 
Untreated 
N=91 
 
Progression, n (%)  
 
9 (30%) 
 
41 (45%) 
 
Deaths for melanoma, n (%) 
 
5 (17%) 
 
32 (35%) 
 
Deaths, n (%)  
 
8 (27%) 
 
38 (42%) 
  
“Treated” indicates patients on β-blockers for ≥1 year. “Untreated” indicates patients 
not on β-blockers or on β-blockers for <1 year.  
 
 
Table 3. Hazard ratio and 95%CI for the association between β-blocker 
use and recurrence and death   
 
 Variables Categories HR Low 
95%CI 
UP 
95%CI 
P-values* 
DFS β-blocker use Yes vs no 0.29 0.12 0.72 0.008 
 Age (years)  1.03 1.01 1.05 0.009 
 Gender female vs male 1.13 0.62 2.07 0.696 
 Breslow (mm)  1.17 1.06 1.30 0.003 
 Ulceration Yes vs no 0.65 0.35 1.18 0.157 
 Mitoses (n.)  1.04 1.01 1.07 0.022 
 Hypertension Yes vs no 0.90 0.46 1.77 0.760 
OS β-blocker use Yes vs no 0.33 0.13 0.83 0.018 
 Age (years)  1.05 1.03 1.08 <.0001 
 Gender female vs male 1.22 0.65 2.29 0.538 
 Breslow (mm)  1.11 0.99 1.26 0.082 
 Ulceration Yes vs no 1.19 0.64 2.24 0.582 
 Mitoses (n.)  1.04 1.00 1.07 0.030 
 Hypertension Yes vs no 0.79 0.39 1.59 0.509 
 
*Results from multivariate Cox regression time-dependent models for use of β-
blocker; 95%CI: 95% Confidence intervals. Disease Free Survival (DFS) and Overall 
Survival (OS)  
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Figure 1: Disease Free Survival and Overall Survival by β-blocker (BB) 
use  
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4.2 Open-label Study for Treatment of Melanoma Patients with β-
blockers - Results 
Of the 79 patients that received a diagnosis of thick melanoma during 
the study period at our clinic, 53 were included in the present study. 
Among the 53 subjects included in the trial, 19 (35%) were eligible for 
treatment with Propranololo (treated group). 34 patients did not have 
criteria for Propranololo treatment, but agreed to participate in the trial 
as control subjects (untreated group). At the time of the diagnosis, we 
administered Propranololo 80 mgR daily to patients in the treated 
group. All patients (treated and untreated) were followed every six 
months as suggested by international guidelines for melanoma patients 
at this stage. The two groups were comparable in terms of demographic 
characteristics and primary prognostic factors at baseline (table 4). We 
had a significant imbalance (P=0.05) only regarding ulceration: 
significant more ulcerated melanoma were present in the treated group. 
After a median follow-up of 3 years, 41.2% (n=14) of the patients in the 
untreated group showed disease progression, which occurred in only 
15.8% (n=3) of the patients in the treated group. It is notable that in the 
untreated group six patients (17.7%) died for melanoma but only two 
patients (10.5%) died in the treated group and one of them died for a 
reason unrelated to melanoma.  
When time to progression was analyzed, log-rank test showed that an 
improved disease-free survival (DFS) for the treated group (P=0.04) 
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(Figure 2). After adjusting for known prognostic factors (age, Breslow 
thickness and ulceration), Cox models confirmed that use of Beta-
Blocker at diagnosis was significantly inversely associated with 
recurrence with about 80% risk reduction for treated patients (HR=0.18, 
95%CI: 0.04-0.89; P=0.03; Table 5). The reduction in risk of Overall 
Survival associated with Beta-Blocker use did not reach statistically 
significance.  
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Table 4: Main clinical and histopathological characteristics of the study population 
divided by β-blockers treatment status 
 
 Treated  
N=19 
Untreated  
N=34 
P-value 
Male gender,  n. (%) 11 (57.9%) 22 (64.7%) 0.62 
Age, Median and IQR 58 (49, 78) 66 (47, 75) 0.88 
Breslow thickness, Median and IQR 2.8 (1.8, 4.3) 2.6 (1.6, 4.0) 0.54 
Sentinel Lymph-node involvement   0.67 
No, n. (%) 7 (39%) 15 (44%)  
Yes, n. (%) 3 (17%) 6 (18%)  
NA, n. (%) 8 (44%) 13 (38%)  
Site of primary melanoma   0.19 
Head or neck, n. (%) 6 (32%) 4 (12%)  
Trunk, n. (%) 4 (21%) 16 (47%)  
Upper limbs, n. (%) 4 (21%) 6 (17%)  
Lower limbs, n. (%) 5 (26%) 8 (24%)  
Histology   0.32 
SSM, n. (%) 7 (37%) 21 (62%)  
Nodular, n. (%) 7 (37%) 12 (35%)  
Other 5 (26%) 1 (3%)  
Lesion with ulceration   0.05 
No, n. (%) 7 (37%) 22 (65%)  
Yes, n. (%) 12 (63%) 12 (35%)  
Number of mitosis   0.25 
0, n. (%) 2 (11%) 1 (3%)  
>0, n. (%) 17 (89%) 33 (37%)  
Patients with hypertension   0.19 
No, n. (%) 13 (68%) 17 (50%)  
Yes, n. (%) 6 (32%) 17 (50%)  
ACEi or Aspirin use   0.28 
No, n. (%) 14 (74%) 20 (59%)  
Yes, n. (%) 5 (26%) 14 (41%)  
Events during follow-up    
Recurrences, n. (%) 3 (16%) 14 (41%) 0.06 
Deaths, n. (%) 2 (11%) 6 (18%) 0.49 
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TABLE 5: Hazard Ratio and 95%CI for melanoma recurrence from Cox 
multivariate regression model 
 
  HR Low 
95%CI 
Up 
95%CI 
P-value 
DFS β-blockers use: yes vs no 0.18 0.04 0.89 0.03 
 Breslow thickness 1.26 0.94 1.69 0.12 
 Age 1.00 0.98 1.02 0.99 
 Lesion with ulceration: yes vs no 1.19 0.39 3.61 0.76 
OS β-blockers use: yes vs no 0.64 0.10 3.96 0.63 
 Breslow thickness 1.60 1.09 2.35 0.02 
 Age 0.99 0.96 1.01 0.28 
 Lesion with ulceration: yes vs no 2.14 0.35 12.95 0.41 
 
 
 
 
Figure 2: Disease free survival by Beta-blocker use  
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5 DISCUSSION 
 
The aforementioned results confirm and strengthen our recent 
observation that β-blockers protect patients with thick cutaneous 
melanoma from disease recurrence and death. No conclusion has been 
drawn until now on the mechanism by which β-blockers protect against 
the progression of CMM.  Besides data obtained in other tumor types, in 
vitro findings in melanoma cell lines or in vivo observations in animal 
models of CMM suggest that β-blockers inhibit tumor and metastasis 
progression at the level of specific mediators that have metastatic and 
proangiogenic potential.  In addition, the recently recognized clinical 
benefit of propranolol in infantile hemangiomas has clearly shown the 
ability of a β-adrenergic receptor blockade to produce antiangiogenic 
effects.  
Infantile hemangiomas (IH) are the most common tumor occurring in 
early childhood, with a prevalence of approximately 5-10% of 
infants75. The vast majority of IH undergo rapid proliferation during 
infancy, particularly in the first months of life, followed by a slow 
involution period that lasts several years. Because this involution occurs 
spontaneously, most IH do not require treatment. Treatment is 
recommended to reduce morbidity and prevent or minimize 
complications. Until recently, corticosteroids in various forms, including 
topical, intralesional, or most commonly systemic, were the mainstay in 
IH treatment; however, response to therapy was varied. In 2008, 
Labreze et al. reported that propranolol, a non-selective β-blocker, was 
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effective in treating eleven patients with IH76. Since that time, there 
have been more than 200 published articles regarding the use of β-
blockers in IH, both systemic and topical, which have revolutionized the 
therapeutic approach to this common condition. The exact mechanism 
of action of β-blockers for the treatment of IH is not yet completely 
understood. However, it is postulated to inhibit growth by at least four 
distinct mechanisms: vasoconstriction, inhibition of angiogenesis or 
vasculogenesis, induction of apoptosis, and recruitment of endothelial 
progenitor cells (EPCs) to the site of the hemangioma77. Of note, β-
adrenergic receptors are expressed on endothelial cells of IH, which are 
found in abundance in the proliferative phase of IH.  
Vascular tone results from a complex interplay of a variety of 
chemokines in the body and their interaction with receptors located on 
endothelial cell surfaces. Several studies have demonstrated that 
activation of β-adrenergic receptors promotes vasodilation. The use of 
β-blockers to mitigate the interaction of adrenaline mediated activation 
of β2-receptors results in vasoconstriction, which leads to reduced 
blood flow within the hemangioma. Activation of β-adrenergic receptors 
leads to increased release of VEGF, which appears to promote both 
angiogenesis and vasculogenesis in IH. Inhibition of these receptors by 
β-blockers results in reduced VEGF production, thereby limiting 
proliferation of vasculature and possibly arresting growth. β-adrenergic 
receptors are thought to play a role in apoptosis. Blockade of β-
receptors induces apoptosis in cultured endothelial cells78, which might 
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contribute to the effectiveness of propranolol in the treatment of IH.  
β-blocker drugs target the β-adrenergic receptor (B-AR). There are 
three B-AR subtypes, distributed predominantly as follows: the β-1 
receptor to myocardium, the β2 receptor to glands and smooth muscle 
of the airways, myocardium, blood vessels, uterus, bladder and gut, and 
the β3 receptor79 to adipose tissue, gastrointestinal tract and 
myocardium. Activation of the β1 subtype causes increases in 
chronotropy, atrioventricular (AV) node conduction and myocardial 
contractility, and reduction in the AV node refractory period. Stimulation 
of the β2 subtype results in bronchodilation, mucus secretion and 
surfactant production, peripheral vasodilation, and relaxation of other 
organ-related smooth muscles. Less is known about the β3 receptor 
subtype. It is thought to have a role in fat metabolism, regulating 
lipolysis and thermogenesis in visceral adipose tissue80. At the cellular 
level, the B-ARs exert their effects via cyclic Adenosine Monophosphate 
(cAMP)-mediated activation of protein kinase A, and may also have 
cAMP-independent effects on calcium-activated potassium channels81-
82. B-AR activity is subject to tight regulation. This is not only achieved 
through the direct effects of agonist, inverse agonist and antagonist 
substances. There exists a negative feedback system, whereby 
ongoing β-agonist stimulation leads to a decrease in receptor density 
and substrate affinity in a process termed “desensitization”. In the short 
term, the receptor can be made relatively insensitive to agonist 
stimulation by a process known as “uncoupling”, with receptor 
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conformational change preventing effective molecular interaction 
between the receptor and cAMP. Then, there is regulation of surface 
cell membrane B-AR numbers, by receptor internalization and 
degradation, and regulation of B-AR messenger RNA (mRNA) 
transcription. There are both immediate and longer-term regulatory 
processes involving cross interactions with other neurotransmitter 
systems (such as the cholinergic system) and inflammatory mediators. 
β-2 receptors are up-regulated and down-regulated by endogenous 
substances such as hormones and cytokines, and by exogenous 
agents. They are down-regulated rapidly in response to agonist agents, 
certain viruses, and pro-inflammatory cytokines83-84. There is an up-
regulatory β-2 receptor response to oral corticosteroids85-86. To 
complicate matters further, as with other complex constituent cellular 
proteins, B- ARs, both β-1 and β-2 subtypes, are subject to genetic 
polymorphism; that is, distinct forms existing within the same 
population, differing at an allelic locus, and occurring more commonly 
than can be accounted for by chance mutation. There are several 
documented polymorphisms of each B-AR subtype, which may have 
differing effects on disease manifestations, clinical severity and 
susceptibility to receptor-active drugs. 
 
Should these mechanisms of β-adrenergic receptors also operate in 
human melanoma, their blockade could be the mechanism underlying 
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the beneficial effect of β-blockers in patients with CMM.  How β-
blockers affect melanoma progression is unknown, although possible 
mechanisms of action may include inhibition of angiogenesis, induction 
of apoptosis, and prevention of catecholamine release. The 
angiogenesis process is crucial in melanoma metastasis growth and 
invasion. β-blockers can inhibit angiogenesis by targeting VEGF, a key 
proangiogenic ligand that induces increased DNA synthesis and 
proliferation of endothelial cells via the downstream MAPK signaling 
pathway. Moreover, down regulation of VEGF expression slows down 
tumor growth and development of metastases. β-blockers also 
demonstrate an antiangiogenic effect with actions beyond the VEGF 
axis. β-blockers reduce expression of two MMPs, MMP-2 and -9, which 
are involved in angiogenesis. Melanoma is highly resistant to cytotoxic 
agents due to inactivation of apoptotic pathways; since β-blockers 
induce apoptosis in different cancer cells and in endothelial cells, it has 
been hypothesized that β-blockers may demonstrate proapoptotic 
activity in melanoma. Furthermore, it has been hypothesized that 
chronic stress can accelerate the process of melanoma metastasis 
because stress is mediated by an angiogenic process. In addition, 
catecholamine-induced up regulation of the cytokines IL-6 and -8 
stimulates tumor advancement. By blocking the release of endogenous 
catecholamines, β-blockers stop promotion of aggressive invasion and 
growth of melanoma cells. Overall, the results from preclinical and 
pharmacoepidemiological studies support the suggestion that β-
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blockers could provide a clinical benefit in melanoma progression 
through inhibition of the pro-metastatic effects of β-AR signaling on 
tumor immune responses and the tumor microenvironment. To date, 
however, pharmacoepidemiological studies examining associations 
between β-blocker use and improved melanoma outcomes have been 
limited in sample size. Future studies should clarify the role in cancer of 
the selective β-AR antagonists compared with nonselective 
receptor antagonists, since the results of preclinical and clinical studies 
in the available literature are conflicting. The β1-selective drugs have 
largely replaced the parent, and nonselective, propranolol, as therapy 
for various cardiovascular conditions. The development of prospective 
clinical trials is critical to clarify definitively the role of β-blockers in 
protecting against the risk of melanoma and its progression, and 
possibly to identify the receptor subtype involved in the protective effect. 
Another important element that must still be clarified concerns the 
possible variations, inhibition or otherwise, by β-AR blockade in specific 
subtypes of melanoma. In particular, as occurred in breast cancer for 
the estrogen receptor, it is possible that there are differences in the 
levels of receptor expression of β-ARs in different subclasses of 
melanoma and, therefore, that inhibition of adrenergic activation by the 
β-blockers may have different effects in different subtypes of 
melanoma. This information can be used to better inform the design of 
randomized clinical studies to address questions regarding the type of 
β-blocker, predictive biomarkers or tumor characteristics, appropriate 
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treatment paradigms and, most importantly, efficacy. The results from 
these randomized studies will be required before targeting of the β-AR 
signaling pathway can be considered a therapeutic option for patients 
with melanoma. However, it is very hard to perform good clinical trials 
with β-blockers that are now out of patent. In addition, the process of a 
clinical trail would be particularly complex because the prognosis of 
melanoma is linked to several confounding factors. 
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